Marking one of the biggest shifts in weight-management policy in decades. With more than 1 billion people worldwide affected by obesity, this decision recognizes that weight is a chronic medical condition, not a short-term issue or a matter of willpower.According to the WHO, GLP-1 medications such as semaglutide, liraglutide, and tirzepatide may be used as long-term treatment options for obesity in adults (not including pregnant women). However, the recommendation is conditional, since more long-term data is needed and access remains limited globally.One key message from the WHO is clear: GLP-1 medications must be paired with comprehensive lifestyle support. This includes structured nutrition, regular physical activity, healthy sleep patterns, and behavioral therapy. Medication alone is not enough, and sustainable weight management requires a multi-layered approach.For individuals looking to support their gut health, cravings, metabolism, and overall balance — whether or not they use prescription GLP-1 drugs — supplements and lifestyle tools can play a meaningful role.

Explore VIYALUM GLP-1 Gut Health Supplement